跳至主要内容
临床试验/NCT00135824
NCT00135824已完成4 期

Local Tolerability and Safety of Povidone K25 (Artificial Tears Containing Povidone) vs. Placebo in Healthy Volunteers

Novartis2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2004年3月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
30
试验地点
2
主要终点
ocular discomfort by using a visual analogue scale (VAS)

研究概览

简要总结

Instillation of artificial tears is standard treatment in dry eye syndrome and in patients experiencing dry eye symptoms when wearing contact lenses. Povidone K25 eye drops (povidone) is an isotonic solution containing povidone to simulate normal tears viscosity. Safety and local tolerability of Povidone K25 is evaluated in healthy volunteers in comparison to placebo eye drops.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects
  • Older than 18 years
  • Ocular discomfort less than 20 mm on 100 mm visual analogue scale (VAS) prior to treatment

排除标准

  • Known hypersensitivity to any of the constituents of the medications
  • Known allergic disposition (e.g. hay fever)
  • Wearing of contact lenses
  • Any kind of current eye disease (e.g. dry eye)
  • Additional exclusion criteria are defined in the protocol

结局指标

主要结局

ocular discomfort by using a visual analogue scale (VAS)

次要结局

  • slit lamp assessment (conjunctival edema, palpebral hyperemia, lid edema)
  • adverse events

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验